Blockade of SIRPα-CD47 axis by anti-SIRPα antibody enhances anti-tumor activity of DXd antibody-drug conjugates

Signal regulatory protein Alpha (SIRPα) is an immune inhibitory receptor on myeloid cells including Macrophages and dendritic cells, which binds to CD47, a ubiquitous self-associated molecule. SIRPα-CD47 interaction is exploited by Cancer cells to suppress anti-tumor activity of myeloid cells, therefore emerging as a novel immune checkpoint for Cancer Immunotherapy. In blood Cancer, several SIRPα-CD47 blockers have shown encouraging monotherapy activity. However, the anti-tumor activity of SIRPα-CD47 blockers in solid Tumors seems limited, suggesting the need for combination therapies to fully exploit the myeloid immune checkpoint in solid Tumors. Here we tested whether combination of SIRPα-CD47 blocker with antibody-drug conjugate bearing a Topoisomerase I inhibitor DXd (DXd-ADC) would enhance anti-tumor activity in solid Tumors. To this end, DS-1103a, a newly developed anti-human SIRPα antibody (Ab), was assessed for the potential combination benefit with datopotamab deruxtecan (Dato-DXd) and trastuzumab deruxtecan (T-DXd), DXd-ADCs targeting human trophoblast cell-surface antigen 2 and human epidermal growth factor receptor 2, respectively. DS-1103a inhibited SIRPα-CD47 interaction and enhanced antibody-dependent cellular phagocytosis of Dato-DXd and T-DXd against human Cancer cells. In a whole Cancer cell vaccination model, vaccination with DXd-treated Cancer cells led to activation of tumor-specific T cells when combined with an anti-mouse SIRPα (anti-mSIRPα) Ab, implying the benefit of combining DXd-ADCs with anti-SIRPα Ab on anti-tumor immunity. Furthermore, in syngeneic mouse models, both Dato-DXd and T-DXd combination with anti-mSIRPα Ab showed stronger anti-tumor activity over the monotherapies. Taken together, this study provides a preclinical rationale of novel therapies for solid Tumors combining SIRPα-CD47 blockers with DXd-ADCs.